

FORM PTO-1449

MAILED DATE CANCELLED

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P0718P2C1D1C1

Serial No.

09/925,179

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Jardieu et al.

Filing Date

08 Aug 2001

Group

3728

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
DB ↓	1	08/146,206		Carter et al.			17.11.93
	2	4,629,783		Cosand			16.12.86
	3	4,714,759	22.12.87	Whitaker, Jr.			
	4	4,861,579	29.08.89	Meyer et al.			
	5	4,940,782	10.07.90	Rup et al.			
	6	5,428,133	11.12.91	Chang, T.			
	7	5,585,089	17.12.96	Queen et al.			07.06.95
	8	5,821,337	13.10.98	Carter et al.			

RECEIVED

FEB 14 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
DB ↓	9	255,249	03.02.88	EPO				
	10	263,655	13.04.88	EPO				
	11	58-156285	17.09.83	JAPAN				
	12	WO 89/04834	01.06.89	PCT				
	13	WO 89/06138	13.07.89	PCT				
	14	WO 90/07861	26.07.90	PCT				
	15	WO 91/09967	11.07.91	PCT				
	16	WO 91/09968		PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

DB ↓	17	Baniyash et al., "Anti-IgE monoclonal antibodies directed at the Fc <sub>ε</sub> receptor binding site" <u>Molecular Immunology</u> 25(8):705-711 (1988)
	18	Baniyash et al., "Inhibition of IgE Binding to Mast Cells and Basophils by Monoclonal Antibodies to Murine IgE" <u>European Journal of Immunology</u> 14:799-807 (1984)
	19	Baniyash, "Immunochemical Characterization of the Interaction Between Immunoglobulin E and Its Receptor" <u>Weizmann Institute of Science</u> (Thesis) (May 1986)
	20	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990)
	21	Burt et al., "Analysis of the interaction between rat immunoglobulin E and rat mast cells using anti-peptide antibodies" <u>Molecular Immunology</u> 24(4):379-389 (1987)
	22	Burt et al., "Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides" <u>European Journal of Immunology</u> 17:437-440 (1987)
	23	Casale et al., "Recombinant Human Monoclonal Anti-IgE Therapy in Allergic Rhinitis" <u>Journal Allergy Clinical Immunology</u> (Abstract) 97(1):Part 3 (1996)
	24	Conrad et al., "The Interaction of Human and Rodent IgE with the Human Basophil IgE Receptor" <u>J. of Immunology</u> 130(1):327-333 (1983)
↓	25	Conrad, D.H., "FcεRII/CD23: The low affinity receptor for IgE" <u>Ann. Rev. Immunol.</u> 8:623-639 (1990)

Examiner

Daniel Blumenthal

Date Considered

9/3/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce

FEB 08 2002

Sheet 2 of 4

MAIL DATE CANCELLED

App. Docket No.

PO 22P2C1D1C1

Serial No.

09/925,179

Applicant

Jardieu et al.

Filing Date

08 Aug 2001

Group

3728

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

26	Deisenhofer, J., "Crystallographic Refinement and Atomic Models of a Human Fc Fragment and its complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution" <u>Biochemistry</u> 20(9):2361-2370 (April 28, 1981)
27	Emery et al., "Humanised monoclonal antibodies for therapeutic applications" <u>Exp. Opin. Invest. Drugs</u> 3(3):241-251 (1994)
28	Geha et al., "IgE sites relevant for binding to type 1 Fc epsilon (FCER) receptors on mast cells" <u>J. Allergy &amp; Clin. Immunol.</u> (Abstract No. 20) 79(1):129 (1987)
29	Gillies et al., "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities" <u>Hum. Antibod. Hybridomas</u> 1(1):47-54 (1990)
30	Glennie et al., "Preparation and Performance of Bispecific F(ab') <sub>2</sub> Antibody Containing Thioether-Linked Fab'γ Fragments" <u>J. Immunol.</u> 139(7):2367-2375 (October 1, 1987)
31	Hakimi et al., "The α subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding" <u>Journal of Biological Chemistry</u> 265(36):22079-22081 (1990)
32	Helm et al., "Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε-chain fragment of 76 amino acids" <u>Proc. Natl. Acad. Sci.</u> 86:9465-9469 (December 1989)
33	Helm et al., "Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E" <u>Journal of Biological Chemistry</u> 271(13):7494-7500 (March 29, 1996)
34	Helm et al., "The mast cell binding site on human immunoglobulin E" <u>Nature</u> 331:180-183 (January 14, 1988)
35	Hoffman, D. R., "Enzyme-linked immunosorbent assays (ELISA) for immunoglobulin E and blocking antibodies" <u>Methods in Enzymology</u> , Chapter 45, 73:656-666 (1981)
36	Hook et al., "Monoclonal Antibodies Defining Epitopes on Human IgE" <u>Molecular Immunology</u> 28(6):631-639 (1991)
37	Ishizaka et al., "Mechanisms of passive sensitization III. Number of IgE Molecules and Their Receptor Sites on Human Basophil Granulocytes" <u>J. Immunol.</u> 111(2):500-511 (Aug 1973)
38	Ishizaka, K., "Immunoglobulin E (IgE)" <u>Methods in Enzymology</u> 116(Part II):76-94 (1985)
39	Jefferis, R., "Structure-function relationships in human immunoglobulins" <u>Netherlands J. Medicine</u> 39:188-198 (1991)
40	Kabat <u>Sequences of Proteins of Immunological Interest</u> (Fourth Ed.), 4th edition pps 41-42, 167-168 (1987)
41	Kahan, "Immunosuppressive therapy" <u>Current Opinion in Immunology</u> 4(5):553-560 (Oct 1992)
42	Kulczycki et al., "The Interaction of IgE with Rat Basophilic Leukemia Cells, Evidence for Specific Binding of IgE" <u>Journal of Experimental Medicine</u> 139:600-616 (1974)
43	Kumar et al., "Amino acid variations at a single residue in an autoimmune peptide, etc." <u>P.N.A.S. USA</u> 87:1337-1341 (Feb 1990)
44	Kurokawa et al., "Expression of human immunoglobulin E ε chain cDNA in E. coli" <u>Nucleic Acids Research</u> 11(10):3077-3085 (1983)
45	Lazar et al., "Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular &amp; Cellular Biology</u> 8(3):1247-1252 (Mar. 1988)

Examiner

*David Blumel*

Date Considered

9/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce

Sheet 3

TECH CENTER 1500/2900

4

FEB 14 2002

MAIL DATE CANCELLED

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.

P0718P2C1D1C1

Serial No.

09/925,179

Applicant

Jardieu et al.

Filing Date

08 Aug 2001

Group

3728

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

DB	46	Liu et al., "Expression of a biologically active fragment of human IgE $\epsilon$ chain in Escherichia coli" <u>Proc. Natl. Acad. Sci.</u> 81:5369-5373 (September 1984)
	47	Metzger and Kinet, "How Antibodies work: focus on Fc receptors" <u>FASEB J</u> 2(1):3-11 (Jan 1988)
	48	Neurath, A. R., "Use of $^{125}$ I-labeled anti-2,4-dinitrophenyl (DNP) antibodies as a general tracer in solid-phase radioimmunoassays" <u>Methods in Enzymology</u> 73:127-138 (1981)
	49	Nio et al., "Inhibition of histamine release by synthetic human IgE peptide fragments: structure-activity studies" <u>Peptide Chemistry</u> pps. 203-208 (1989)
	50	Nissim et al., "Mapping of the high affinity Fc $\epsilon$ receptor binding site to the third constant region domain of IgE" <u>EMBO Journal</u> 10(1):101-107 (Jan 1991)
	51	Nissim et al., "The Use of Mouse/Human IgE Chimeras to Map the Fc $\epsilon$ R Binding Site of IgE" <u>Methods</u> 8:124-132 (1995)
	52	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990)
	53	Padlan et al., "A model of the Fc of immunoglobulin E" <u>Molecular Immunology</u> 23(10):1063-1075 (1986)
	54	Paul, W.E. ed. <u>Fundamental Immunology</u> , Raven Press, NY, 3rd edition pps. 822-826 (1993)
	55	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)
	56	Rao et al., "Characterization of a Monoclonal Antibody Directed Against the Murine B Lymphocyte Receptor for IgE" <u>Journal of Immunology</u> 138(6):1845-1851 (Mar 15, 1987)
	57	Riechmann et al., "Reshaping human antibodies for therapy" <u>Nature</u> 332(24):323-327 (Mar 1988)
	58	Riske et al., "High Affinity Human IgE Receptor (Fc $\epsilon$ RI). Analysis of functional Domains of the $\alpha$ -Subunit with Monoclonal Antibodies" <u>Journal of Biological Chemistry</u> 266(17):11245-11251 (June 15, 1991)
	59	Robertson et al., "IgE structure-function relationships defined by sequence directed antibodies induced by synthetic peptides" <u>Molecular Immunology</u> 25(2):103-113 (1988)
	60	Robertson et al., "The Isolation of Polypeptides With FSH Suppressing Activity From Bovine Follicular Fluid Which Are Structurally Different to Inhibin" <u>Biochem. and Biophysical Res. Comm.</u> 149(2):744-749 (Dec. 16, 1987)
	61	Roitt et al., "Antigen Receptor Molecules" <u>Immunology</u> , Mosby Limited, 3rd edition pps. 4.8 (1996)
	62	Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity" <u>Proc. Natl. Acad. Sci. USA</u> 79:1979-1983 (1982)
	63	Schwarzbaum et al., "Mapping of murine IgE epitopes involved in IgE-Fc $\epsilon$ receptor interactions" <u>European Journal of Immunology</u> 19:1015-1023 (1989)
	64	"Sequences of Immunological Interest", U.S. Dept. of Health and Human Service Vol. 1 (1991)
V	65	Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995)

Examiner

Daniel Blumberg

Date Considered

9/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce

Patent and Trademark Office

Att'y Docket No.

P0718P2C1D1c

Serial No.

09/925,179

Applicant

Jardieu et al.

Filing Date

08 Aug 2001

Group

3728

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

[illegible]

Examiner

David Blumenthal

Date Considered \_\_\_\_\_

9/3/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
FEB 13 2002  
IC 3700 MAIL ROOM